The second program in our discovery pipeline is an engineered human enzyme that degrades adenosine, work that has generated in vivo proof of concept and is in lead discovery. There are multiple pathways by which adenosine can be produced in the tumor microenvironment. Targeting the immunosuppressive activity of adenosine by enzyme-mediated degradation addresses both diverse sources of adenosine production and a variety of receptor subtypes.
Targeting Small Molecule Mediators of Immune Evasion
Delta’s novel platform technology is expected to generate additional clinical candidates that address other (undisclosed) targets to enhance the activity of the immune system to fight cancer.